Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Silence Therapeutics PLC Sponsored ADR (SLN : NSDQ)

• Company Description    Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom. Number of Employees: 116

• Price / Volume Information    Yesterday's Closing Price: $6.08 Daily Weekly Monthly 20 Day Moving Average: 270,961 shares Shares Outstanding: 47.23 (millions) Market Capitalization: $287.18 (millions) Beta: 1.32 52 Week High: $7.87 52 Week Low: $1.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.73% -14.58% 12 Week 18.06% 16.15% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12 HAMMERSMITH GROVE OFFICE 205 - LONDON,X0 W6 7AP GBR ph: 44-20-3457-6900 fax: - ir@silence-therapeutics.com http://www.silence-therapeutics.com

• General Corporate Information    Officers Craig Tooman - President and Chief Executive Officer and Director Iain Ross - Chairman of the Board of Directors Rhonda Hellums - Chief Financial Officer Dave Lemus - Director Michael Davidson - Director Peer Information Silence Therapeutics PLC Sponsored ADR (GSAC) Silence Therapeutics PLC Sponsored ADR (CASI) Silence Therapeutics PLC Sponsored ADR (ALCD.) Silence Therapeutics PLC Sponsored ADR (OMNN) Silence Therapeutics PLC Sponsored ADR (CGPI.) Silence Therapeutics PLC Sponsored ADR (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 82686Q101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 47.23 Most Recent Split Date: (:1) Beta: 1.32 Market Capitalization: $287.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.36 Price/Cash Flow: - Price / Sales: 11.16 EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -89.29% vs. Previous Quarter: -29.02% ROE 12/31/25 - - 09/30/25 - -61.76 06/30/25 - -67.48 ROA 12/31/25 - - 09/30/25 - -36.62 06/30/25 - -40.47 Current Ratio 12/31/25 - - 09/30/25 - 7.69 06/30/25 - 10.06 Quick Ratio 12/31/25 - - 09/30/25 - 7.69 06/30/25 - 10.06 Operating Margin 12/31/25 - - 09/30/25 - -249.11 06/30/25 - -289.31 Net Margin 12/31/25 - - 09/30/25 - -254.25 06/30/25 - -294.20 Pre-Tax Margin 12/31/25 - - 09/30/25 - -249.61 06/30/25 - -291.12 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©